Cargando…

Consolidation Chemotherapy Rather than Induction Chemotherapy Can Prolong the Survival Rate of Inoperable Esophageal Cancer Patients Who Received Concurrent Chemoradiotherapy

Concurrent chemoradiotherapy (CRT) is regarded as the standard treatment for inoperable esophageal cancers (EC). It is still controversial whether consolidation chemotherapy (CCT) or induction chemotherapy (IC) is beneficial for the patients who received CRT. Therefore, we carried out a retrospectiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Xiaojie, Wu, Mengxing, Gao, Qing, Sun, Xinchen, Ge, Xiaolin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9498234/
https://www.ncbi.nlm.nih.gov/pubmed/36135068
http://dx.doi.org/10.3390/curroncol29090499
_version_ 1784794707746881536
author Xia, Xiaojie
Wu, Mengxing
Gao, Qing
Sun, Xinchen
Ge, Xiaolin
author_facet Xia, Xiaojie
Wu, Mengxing
Gao, Qing
Sun, Xinchen
Ge, Xiaolin
author_sort Xia, Xiaojie
collection PubMed
description Concurrent chemoradiotherapy (CRT) is regarded as the standard treatment for inoperable esophageal cancers (EC). It is still controversial whether consolidation chemotherapy (CCT) or induction chemotherapy (IC) is beneficial for the patients who received CRT. Therefore, we carried out a retrospective analysis at our institution. A total of 186 inoperable EC patients from 20 October 2017 to 7 June 2021 who have previously received CRT were included in our study. The patients were divided into IC + CRT (n = 52), CCRT (n = 64), and CRT + CCT (n = 70) groups according to whether they received induction chemotherapy, consolidation chemotherapy, or not. We used Kaplan–Meier statistics to analyze their 1-, 2-, and 3-year OS. The median follow-up time for the whole group was 14.15 months. The 1-, 2-, 3- year overall survival (OS) for the CCRT group were 72.2%, 52.5%, and 29.5%, and 50.9%, 37.5%, and 25% for the IC + CRT group (p > 0.05). For the CRT + CCT group,1-, 2-, and 3-year OS were 89.8%, 59.0%, and 42.5% (p < 0.05). Adverse reactions in the three groups were mainly graded 0–3. The difference between the three groups was not statistically significant (p > 0.05). For non-surgical EC patients who received CRT, CCT after CRT but not IC before CRT can improve 1-, 2-, and 3-year OS with a low incidence of associated severe adverse effects. As a result, the addition of consolidation chemotherapy to chemoradiotherapy has significant prognostic advantages for inoperable EC patients.
format Online
Article
Text
id pubmed-9498234
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94982342022-09-23 Consolidation Chemotherapy Rather than Induction Chemotherapy Can Prolong the Survival Rate of Inoperable Esophageal Cancer Patients Who Received Concurrent Chemoradiotherapy Xia, Xiaojie Wu, Mengxing Gao, Qing Sun, Xinchen Ge, Xiaolin Curr Oncol Article Concurrent chemoradiotherapy (CRT) is regarded as the standard treatment for inoperable esophageal cancers (EC). It is still controversial whether consolidation chemotherapy (CCT) or induction chemotherapy (IC) is beneficial for the patients who received CRT. Therefore, we carried out a retrospective analysis at our institution. A total of 186 inoperable EC patients from 20 October 2017 to 7 June 2021 who have previously received CRT were included in our study. The patients were divided into IC + CRT (n = 52), CCRT (n = 64), and CRT + CCT (n = 70) groups according to whether they received induction chemotherapy, consolidation chemotherapy, or not. We used Kaplan–Meier statistics to analyze their 1-, 2-, and 3-year OS. The median follow-up time for the whole group was 14.15 months. The 1-, 2-, 3- year overall survival (OS) for the CCRT group were 72.2%, 52.5%, and 29.5%, and 50.9%, 37.5%, and 25% for the IC + CRT group (p > 0.05). For the CRT + CCT group,1-, 2-, and 3-year OS were 89.8%, 59.0%, and 42.5% (p < 0.05). Adverse reactions in the three groups were mainly graded 0–3. The difference between the three groups was not statistically significant (p > 0.05). For non-surgical EC patients who received CRT, CCT after CRT but not IC before CRT can improve 1-, 2-, and 3-year OS with a low incidence of associated severe adverse effects. As a result, the addition of consolidation chemotherapy to chemoradiotherapy has significant prognostic advantages for inoperable EC patients. MDPI 2022-09-02 /pmc/articles/PMC9498234/ /pubmed/36135068 http://dx.doi.org/10.3390/curroncol29090499 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Xia, Xiaojie
Wu, Mengxing
Gao, Qing
Sun, Xinchen
Ge, Xiaolin
Consolidation Chemotherapy Rather than Induction Chemotherapy Can Prolong the Survival Rate of Inoperable Esophageal Cancer Patients Who Received Concurrent Chemoradiotherapy
title Consolidation Chemotherapy Rather than Induction Chemotherapy Can Prolong the Survival Rate of Inoperable Esophageal Cancer Patients Who Received Concurrent Chemoradiotherapy
title_full Consolidation Chemotherapy Rather than Induction Chemotherapy Can Prolong the Survival Rate of Inoperable Esophageal Cancer Patients Who Received Concurrent Chemoradiotherapy
title_fullStr Consolidation Chemotherapy Rather than Induction Chemotherapy Can Prolong the Survival Rate of Inoperable Esophageal Cancer Patients Who Received Concurrent Chemoradiotherapy
title_full_unstemmed Consolidation Chemotherapy Rather than Induction Chemotherapy Can Prolong the Survival Rate of Inoperable Esophageal Cancer Patients Who Received Concurrent Chemoradiotherapy
title_short Consolidation Chemotherapy Rather than Induction Chemotherapy Can Prolong the Survival Rate of Inoperable Esophageal Cancer Patients Who Received Concurrent Chemoradiotherapy
title_sort consolidation chemotherapy rather than induction chemotherapy can prolong the survival rate of inoperable esophageal cancer patients who received concurrent chemoradiotherapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9498234/
https://www.ncbi.nlm.nih.gov/pubmed/36135068
http://dx.doi.org/10.3390/curroncol29090499
work_keys_str_mv AT xiaxiaojie consolidationchemotherapyratherthaninductionchemotherapycanprolongthesurvivalrateofinoperableesophagealcancerpatientswhoreceivedconcurrentchemoradiotherapy
AT wumengxing consolidationchemotherapyratherthaninductionchemotherapycanprolongthesurvivalrateofinoperableesophagealcancerpatientswhoreceivedconcurrentchemoradiotherapy
AT gaoqing consolidationchemotherapyratherthaninductionchemotherapycanprolongthesurvivalrateofinoperableesophagealcancerpatientswhoreceivedconcurrentchemoradiotherapy
AT sunxinchen consolidationchemotherapyratherthaninductionchemotherapycanprolongthesurvivalrateofinoperableesophagealcancerpatientswhoreceivedconcurrentchemoradiotherapy
AT gexiaolin consolidationchemotherapyratherthaninductionchemotherapycanprolongthesurvivalrateofinoperableesophagealcancerpatientswhoreceivedconcurrentchemoradiotherapy